BioCentury | Jul 18, 2011
Company News

NuRx, QuantRx diagnostic news

...QN Diagnostics LLC. The JV was formed last July to develop and commercialize point-of-care diagnostics. NuRx...
...ownership of the JV in exchange for 12 million shares valued at $240,000 based on NuRx's...
...million warrants in QuantRx held by NuRx. Last year, QuantRx had announced plans to acquire NuRx...
BioCentury | Jan 6, 2011
Targets & Mechanisms

More mileage out of myelin

...Phase II/III testing to treat liver cancer; and NRX4204 from Vitae Pharmaceuticals Inc. and partner NuRx Pharmaceuticals Inc....
...Nagoya, Japan Louis Pasteur University , Illkrich, France Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland NuRx Pharmaceuticals Inc....
BioCentury | Jun 24, 2010
Distillery Therapeutics

Indication: Cancer

...treat cutaneous T cell lymphoma (CTCL). NRX4204, an RXRa agonist from Vitae Pharmaceuticals Inc. and NuRx Pharmaceuticals Inc....
BioCentury | Feb 8, 2010
Company News

NuRx, QuantRx deal

...QuantRx will acquire partner NuRx in a stock deal valued at $15.2 million based on QuantRx's...
...day before the deal was announced. NuRx shareholders will receive 1.5 QuantRx shares for every NuRx...
...and competitive position in the point-of-care diagnostic market. The deal is subject to approval by NuRx...
BioCentury | Aug 10, 2009
Company News

NuRx, QuantRx deal

...RapidSense diagnostics technology, including a line of CLIA-waived quantitative lateral flow diagnostics for undisclosed indications. NuRx...
...and facilities to the JV for a monthly fee, with an initial fee of $250,000. NuRx...
...$1.25. QuantRx closed at $0.50 on July 30, the day before the deal was announced. NuRx Pharmaceuticals Inc....
BioCentury | Mar 31, 2008
Clinical News

NuRx, Vitae preclinical data

...of the mammary tumors when used therapeutically. Data were published in Clinical Cancer Research. NuRx Pharmaceuticals Inc. (OTCBB:NURX...
BioCentury | Mar 31, 2008
Clinical News

NRX4204: Phase I started

...NuRx (formerly Quest Group International Inc. ) began a Phase I trial of oral NRX4204. The company...
...exclusive rights to the compound from Vitae last year (see BioCentury, May 21, 2007). NuRx Pharmaceuticals Inc. (OTCBB:NURX...
BioCentury | May 21, 2007
Company News

Quest Group, Vitae deal

...Phase I testing to treat cancer by early next year. Financial terms were not disclosed. Quest Group...
BioCentury | May 21, 2007
Company News

Quest Group board of directors update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Hired: Harin Padma-Nathan as CEO, while remaining CSO of Insyght Interactive Inc. WIR Staff cancer...
BioCentury | May 21, 2007
Company News

Quest Group scientific advisory board update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Appointed: Parkash Gill, professor of medicine at the University of Southern California's Keck School of Medicine, as chairman WIR Staff cancer...
Items per page:
1 - 10 of 11
BioCentury | Jul 18, 2011
Company News

NuRx, QuantRx diagnostic news

...QN Diagnostics LLC. The JV was formed last July to develop and commercialize point-of-care diagnostics. NuRx...
...ownership of the JV in exchange for 12 million shares valued at $240,000 based on NuRx's...
...million warrants in QuantRx held by NuRx. Last year, QuantRx had announced plans to acquire NuRx...
BioCentury | Jan 6, 2011
Targets & Mechanisms

More mileage out of myelin

...Phase II/III testing to treat liver cancer; and NRX4204 from Vitae Pharmaceuticals Inc. and partner NuRx Pharmaceuticals Inc....
...Nagoya, Japan Louis Pasteur University , Illkrich, France Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland NuRx Pharmaceuticals Inc....
BioCentury | Jun 24, 2010
Distillery Therapeutics

Indication: Cancer

...treat cutaneous T cell lymphoma (CTCL). NRX4204, an RXRa agonist from Vitae Pharmaceuticals Inc. and NuRx Pharmaceuticals Inc....
BioCentury | Feb 8, 2010
Company News

NuRx, QuantRx deal

...QuantRx will acquire partner NuRx in a stock deal valued at $15.2 million based on QuantRx's...
...day before the deal was announced. NuRx shareholders will receive 1.5 QuantRx shares for every NuRx...
...and competitive position in the point-of-care diagnostic market. The deal is subject to approval by NuRx...
BioCentury | Aug 10, 2009
Company News

NuRx, QuantRx deal

...RapidSense diagnostics technology, including a line of CLIA-waived quantitative lateral flow diagnostics for undisclosed indications. NuRx...
...and facilities to the JV for a monthly fee, with an initial fee of $250,000. NuRx...
...$1.25. QuantRx closed at $0.50 on July 30, the day before the deal was announced. NuRx Pharmaceuticals Inc....
BioCentury | Mar 31, 2008
Clinical News

NuRx, Vitae preclinical data

...of the mammary tumors when used therapeutically. Data were published in Clinical Cancer Research. NuRx Pharmaceuticals Inc. (OTCBB:NURX...
BioCentury | Mar 31, 2008
Clinical News

NRX4204: Phase I started

...NuRx (formerly Quest Group International Inc. ) began a Phase I trial of oral NRX4204. The company...
...exclusive rights to the compound from Vitae last year (see BioCentury, May 21, 2007). NuRx Pharmaceuticals Inc. (OTCBB:NURX...
BioCentury | May 21, 2007
Company News

Quest Group, Vitae deal

...Phase I testing to treat cancer by early next year. Financial terms were not disclosed. Quest Group...
BioCentury | May 21, 2007
Company News

Quest Group board of directors update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Hired: Harin Padma-Nathan as CEO, while remaining CSO of Insyght Interactive Inc. WIR Staff cancer...
BioCentury | May 21, 2007
Company News

Quest Group scientific advisory board update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Appointed: Parkash Gill, professor of medicine at the University of Southern California's Keck School of Medicine, as chairman WIR Staff cancer...
Items per page:
1 - 10 of 11